Coherus BioSciences Appoints Patrick O’Brien as Senior Vice President, Investor Relations

REDWOOD CITY, Calif., May 16, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late stage clinical, as well as pipeline products, is pleased to announce the appointment of Patrick O’Brien as Senior Vice President of Investor Relations. Mr. O’Brien joins Coherus with more than 15 years of established buy-side and sell-side experience in investor relations and most recently led an award-winning biotechnology investor relations program.

“We are very gratified to have an investor relations executive of Mr. O’Brien’s caliber choose to join the Coherus team at this time,” said Denny Lanfear, President and Chief Executive Officer of Coherus. “2016 is a transformational year for Coherus, as we prepare our product registration filings and accelerate our second wave of products. Patrick’s experience, insights, and relationships with the investment community will be critical to effectively communicating our objectives, strategies, and progress to analysts and investors.”

Mr. O’Brien has extensive experience in investor relations within the biotechnology sector. He comes to Coherus from Gilead Sciences, Inc. where, as Vice President of IR, he led the #1 ranked team by both buy-side and sell-side analysts in the healthcare / biotechnology category for 2014, 2015 and 2016. Additionally, Patrick ranked as the #1 IR professional in the biotechnology categories in Institutional Investor Magazine for both the buy-side and sell-side for 2014, 2015 and 2016. Patrick earned his Bachelor’s degree from Loyola University, and MBA from Northwestern’s Kellogg Graduate School of Management.

About Coherus BioSciences, Inc.

Coherus is a leading pure-play global biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products, including CHS-5217 (bevacizumab biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional information, please visit


Patrick O’Brien
Coherus BioSciences, Inc.
+1 (650) 649-3527

Keith Vendola, M.D.
Coherus BioSciences, Inc.
+1 (650) 437-6239

Source:Coherus BioSciences, Inc.